BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//The BioCalendar - ECPv6.16.3//NONSGML v1.0//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:The BioCalendar
X-ORIGINAL-URL:https://thebiocalendar.com
X-WR-CALDESC:Events for The BioCalendar
REFRESH-INTERVAL;VALUE=DURATION:PT1H
X-Robots-Tag:noindex
X-PUBLISHED-TTL:PT1H
BEGIN:VTIMEZONE
TZID:America/Los_Angeles
BEGIN:DAYLIGHT
TZOFFSETFROM:-0800
TZOFFSETTO:-0700
TZNAME:PDT
DTSTART:20240310T100000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:-0700
TZOFFSETTO:-0800
TZNAME:PST
DTSTART:20241103T090000
END:STANDARD
BEGIN:DAYLIGHT
TZOFFSETFROM:-0800
TZOFFSETTO:-0700
TZNAME:PDT
DTSTART:20250309T100000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:-0700
TZOFFSETTO:-0800
TZNAME:PST
DTSTART:20251102T090000
END:STANDARD
BEGIN:DAYLIGHT
TZOFFSETFROM:-0800
TZOFFSETTO:-0700
TZNAME:PDT
DTSTART:20260308T100000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:-0700
TZOFFSETTO:-0800
TZNAME:PST
DTSTART:20261101T090000
END:STANDARD
END:VTIMEZONE
BEGIN:VEVENT
DTSTART;TZID=America/Los_Angeles:20251202T080000
DTEND;TZID=America/Los_Angeles:20251202T113000
DTSTAMP:20260530T045414
CREATED:20251125T142613Z
LAST-MODIFIED:20251125T142613Z
UID:9582-1764662400-1764675000@thebiocalendar.com
SUMMARY:Philadelphia Life Sciences Conference
DESCRIPTION:Greater Philadelphia sits at the forefront of a dynamic life sciences evolution\, where strategic decision-making today will shape the trajectory of the region’s biotech and innovation economy for years to come. As funding landscapes shift\, groundbreaking research emerges\, and tenant demands evolve\, stakeholders across commercial real estate\, including developers\, investors\, and brokers\, need critical insights to navigate the complex marketplace. \nPhiladelphia boasts robust research institutions\, cutting-edge talent\, and a collaborative ecosystem uniquely positioned to nurture startups into thriving enterprises. But retaining these innovative companies locally demands strategic investment and thoughtfully designed infrastructure. This event provides essential guidance on fostering a robust “bench-to-market” pipeline\, securing creative financing amid challenging market conditions\, and capitalizing on opportunities poised to reshape the region. \nJoin industry leaders\, innovators\, and policymakers as they delve deep into strategies for attracting and retaining tenants\, leveraging financial tools\, and building the resilient and adaptive infrastructure needed for Philadelphia’s sustained growth in life sciences real estate. \nWhat You Will Learn: \n\nPhiladelphia’s “Secret Sauce” for Startups: The city offers a unique blend of assets for life science entrepreneurs – world-class research institutions producing cutting-edge IP and talent\, plus a culture of collaboration where academia\, industry\, and government actively work together. Hear how this has created fertile ground for startups. For instance\, the University City Science Center’s expansion with Wexford and Ventas now spans 11 city blocks and houses 200+ companies\, providing critical lab space and networking for entrepreneurs. We’ll hear success stories of companies that started in a campus lab or incubator and grew into standalone firms\, illustrating the “incubation-to-graduation” pipeline now established in Philly .\nRetaining Homegrown Companies: What does it takes to keep companies in the region through their growth stages. Philadelphia’s “bench-to-market” pathway is increasingly robust\, a company can start at a university lab\, launch at a BioLabs or B+Labs incubator\, then move up to a larger space in the city\, and even establish manufacturing at sites like the Navy Yard\, all without leaving Greater Philadelphia . This continuum (rare among cities) is a selling point. Hear how to leverage initiatives and how to address any gaps so that Philly’s brightest biotech companies scale up locally rather than relocate.\nCapital Markets and Development Strategy: Higher interest rates and cautious lenders have forced developers to be more strategic\, often requiring pre-leases for new projects. Experts will share how they are securing financing\, using creative tools (C-PACE\, JV partnerships) and timing projects to ride out the storm .\nPhiladelphia’s Competitive Edge: Highlight fundamentals keeping Philly on top – huge research institutions and NIH funding\, a rise in lab rents in University City\, and abundant STEM talent. These factors\, plus a cost advantage\, position the region to rebound strongly as confidence returns.\nDeveloper Financing Strategies in a Tight Market: With traditional debt financing more expensive\, developers have had to get creative to fund projects. Panelists will share firsthand experiences structuring deals\, (including C-PACE and regional bank loans) amid a tough lending environment. Examine how life science projects can leverage public sector support and how some developers are deferring or phasing projects to align with capital availability.\nOpportunities on the Horizon: Despite the current caution\, Philadelphia’s fundamentals continue to attract interest. Are developers quietly assembling capital to pounce on distressed lab assets or conversions at a discount? Will the suburban markets (with their lower costs and existing pharma infrastructure) see a faster revival? And how can public initiatives be leveraged to catalyze public-private investment in new research facilities or workforce training centers?
URL:https://thebiocalendar.com/event/philadelphia-life-sciences-conference/
LOCATION:Philadelphia\, Philadelphia\, PA\, United States
CATEGORIES:Summit
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/Los_Angeles:20251202T080000
DTEND;TZID=America/Los_Angeles:20251202T120000
DTSTAMP:20260530T045414
CREATED:20251125T142457Z
LAST-MODIFIED:20251125T142457Z
UID:9581-1764662400-1764676800@thebiocalendar.com
SUMMARY:2025 Boston Biotech Summit
DESCRIPTION:What You’ll Learn: \n\nHow will lower interest rates influence biotech funding\, investment flows\, and real estate capital allocation in 2025?\nWith a record volume of new lab and GMP supply delivering this year\, how can owners make their assets stand out in a crowded market?\nIs renewed activity in biotech IPOs and venture funding a sign of sustained momentum heading into 2026?\nHow is Boston’s biotech ecosystem continuing to foster innovation\, and what distinctive advantages will support its rebound?\nWhat impact have major development projects across Greater Boston had on advancing the region’s life sciences growth and competitiveness?\nAs vacancy climbs above 30% in Greater Boston\, is the balance of power shifting further toward tenants\, and what will they expect from new space?\nHow is technology driving the demand for flexible\, adaptable labs and GMP facilities that can evolve with science?\nIn what ways has tenant demand for modular layouts\, spec suites\, and shorter lease terms reshaped leasing dynamics in 2025?\nWhy is biomanufacturing becoming a stabilizing force for the market\, and how are GMP facilities attracting both tenants and investors?\n\nHow you’ll do more business: \nConnect with industry leaders to explore emerging leasing dynamics\, gain valuable investor insights and discover cutting-edge innovations in workspace design. Gain insights into the trade-offs and advantages associated with advanced manufacturing techniques and Good Manufacturing Practice\, or GMP\, standards in biotech. Explore topics like sustainable facility design\, power solutions\, access considerations and other crucial aspects that can enhance your business strategy.  \nWho attends: \nInvestors\, owners\, developers\, tenants\, end users\, brokers\, lawyers\, designers\, contractors\, architects\, property managers and more!
URL:https://thebiocalendar.com/event/2025-boston-biotech-summit/
LOCATION:Somerville\, Somerville\, MA\, United States
CATEGORIES:Summit
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/Los_Angeles:20251202T110000
DTEND;TZID=America/Los_Angeles:20251202T120000
DTSTAMP:20260530T045414
CREATED:20251106T150004Z
LAST-MODIFIED:20251106T150004Z
UID:9444-1764673200-1764676800@thebiocalendar.com
SUMMARY:Streamline the Critical Path for Gene Therapy: Key Considerations for the AAV Analytical Lifecycle
DESCRIPTION:AAV vectors offer clear benefits for gene therapy\, and continued advances in technology have increased target specificity\, improved potency\, and intensified production efficiency.  Even with significant attention early in development\, analytical activities for gene therapy often land on the critical path.   \nThis webinar provides considerations for phase-appropriate AAV characterization and release activities from pre-clinical to late-phase products. Early-stage analytical topics will address how to leverage platform analytics\, client-specific methods and transfers\, formulation verifications\, tox material testing\, and stability. Late-stage focus will review continued development activities\, timing of method validation\, IPC verifications\, and data trending. We will discuss potential challenges in validation of late-stage analytics for PPQ and late-phase testing and paths for maturation of platform and product-specific analytics.
URL:https://thebiocalendar.com/event/streamline-the-critical-path-for-gene-therapy-key-considerations-for-the-aav-analytical-lifecycle/
ATTACH;FMTTYPE=image/png:https://thebiocalendar.com/wp-content/uploads/2025/11/12-02-25-Catalent-eBlast-700x200-1.png
END:VEVENT
END:VCALENDAR